Remember the company said Q4 which is Oct/Nov/Dec for the results.
One piece of news is kind of expected in Nov - the FDA response to the Type A request.
Then again they are busy so that FDA decision might be delayed longer than usual.
"Mesoblast has formally requested a Type A meeting with the FDA to discuss a potential accelerated approval of
the Biologics License Application (BLA) for remestemcel-L for the treatment of SR-aGVHD in children,
with an additional randomized controlled study in patients 12 years and older as a post-approval
requirement. Mesoblast expects this meeting will occur in November"
Certainly more and more likely that most news will be out in the next 45 days
Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial, page-326
-
- There are more pages in this discussion • 67 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.055(5.24%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.13 | $1.04 | $6.781M | 6.207M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 43856 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 66000 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |